Heterogeneity of T1DM raises questions for therapy

Nature Reviews Endocrinology

Volumn 8, Issue 2, 2012, Pages 78-80

  Pozzilli, Paolo ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; HEMOGLOBIN A1C; PLACEBO; REACTIVE OXYGEN METABOLITE; TEPLIZUMAB;

AREA UNDER THE CURVE; CELL DESTRUCTION; CELL FUNCTION; CELL HETEROGENEITY; CYTOTOXICITY; DIABETIC PATIENT; DISEASE COURSE; HLA TYPING; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; ANIMAL; ENDOCRINOLOGY; GENETIC HETEROGENEITY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; TIME;

ANIMALS; DIABETES MELLITUS, TYPE 1; ENDOCRINOLOGY; GENETIC HETEROGENEITY; HUMANS; IMMUNOPHENOTYPING; MICE; MOLECULAR TARGETED THERAPY; TIME FACTORS;

EID: 84856436834     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.228     Document Type: Review

References (10)

1. Bottino, R. et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 53, 2559-2568 (2004). (Pubitemid 39299262)
2. Tran, P. O et al. Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress. J. Biol. Chem. 279, 53988-53993 (2004). (Pubitemid 40053130)
3. Thayer, T. C, et al. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes 60, 2144-2151 (2011).
4. Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412-419 (2011).
5. Sherry, N. et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487-497 (2011).
6. Klinke, D. J. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS ONE 6, e26873 (2011).
7. Buzzetti, R. et al.C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 60, 3067-3072 (2011).
8. Lind, M. et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378, 140-146 (2011).
9. Sun, J. K. et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care 34, 968-974 (2011).
10. Thomas, M. C, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 54, 2669-2677 (2011).